Cartalax Research: Bioregulator Peptide and Cartilage Studies

Last updated: June 2026

A Cartalax research compound is a synthetic short peptide bioregulator derived from cartilage tissue fractions. Khavinson lab research first described this compound. Lab studies have studied its effects on gene output in cartilage cell models. Researchers measured changes in mRNA levels in treated cell lines compared to controls. Research-grade Cartalax needs ≥99% purity confirmed by HPLC and mass spec before any lab use.

Next Level Pharm is a US supplier of research-grade peptides, including Cartalax. Each vial is verified to ≥99% purity by HPLC and mass spec. The COA ships with every order and includes a traceable lot number. The average purity across the last 100 batches is 99.4%. This compound is for lab research use only.

Understanding Cartalax and its tissue of origin helps researchers plan lab protocols. It belongs to a class of short tissue-derived peptides studied in cell and animal models. These compounds are called bioregulator peptides in Khavinson lab literature.

Key Takeaways

1. Cartalax Is a Short Four-Amino Acid Peptide: It was derived from cartilage tissue fractions in Khavinson lab research. This tissue origin shapes the research questions studied.
2. Cartilage Tissue Is the Source of Origin: Lab studies used cartilage-type cell lines. Cell culture work checked gene output changes vs untreated controls.
3. Cell Culture Studies Studied Gene Output Changes: Treated cell lines showed changes in mRNA levels in vitro. These findings do not apply to human biology directly.
4. Mass Spec Easily Confirms Low Molecular Weight: Cartalax has a low molecular weight as a short peptide. Mass spec identifies its mass with high precision.
5. Research-Grade Cartalax Is for Lab Use Only: It is not FDA-approved. Each batch ships with a COA showing HPLC and mass spec data.

Researchers sourcing Cartalax for lab use should verify the COA before any study. HPLC must confirm ≥99% purity and mass spec must confirm the correct molecular weight. Both tests should appear on the COA for every production batch.

What Is Cartalax and Where Does It Come From?

Cartalax is a synthetic short peptide bioregulator first described in Khavinson lab research. The compound was derived from cartilage tissue fractions by acid extraction and column separation. The resulting peptide chain was later reproduced by lab synthesis for research purposes.

Synthetic Cartalax is now made by solid-phase peptide synthesis (SPPS). This method builds the amino acid chain step by step on a solid resin. The chain is then released and purified. SPPS allows exact replication of the natural sequence with controlled purity.

According to a study in PubMed (2016), Khavinson and colleagues described tissue-specific effects of short cartilage-derived peptides on gene output in cell models. The research used in vitro methods and focused on cartilage-type cell lines. These findings do not apply to human clinical use.

What Is the Sequence and Structure of Cartalax?

Cartalax is a short peptide, meaning it is a chain of exactly four amino acids. As a short four-amino acid compound, it has a low molecular weight compared to longer peptides. Short peptides like Cartalax can enter cell nuclei and interact with chromatin in lab studies.

The low molecular weight is a research advantage for mass spec verification. Mass spec can identify short peptide masses with high detail. A correct result confirms the compound is the intended peptide and not a truncated or modified form.

According to a review in Molecules (2021), short four-amino acid peptides from organ tissue fractions were shown to interact with chromatin near gene promoters. Cell culture studies confirmed these findings in vitro. Changes in mRNA output were measured in treated cells vs controls.

What Did Cell Culture Studies Show About Cartalax?

Cell culture studies used cartilage-type cell lines to study Cartalax effects. Researchers measured gene output changes after Cartalax treatment in vitro. Changes in mRNA levels for cartilage-linked genes have been reported in treated cells compared to untreated controls.

The proposed mechanism involves the short peptide chain entering the cell nucleus and binding chromatin regions. This binding may alter gene switch access at promoter sites. These changes have been found in cell culture assays and not in living human tissue.

What Did Animal Model Studies Find for Cartalax?

Animal model research has extended the cell culture findings for Cartalax. Rodent model studies studied tissue-linked markers after treatment with the compound. Researchers found changes in cartilage tissue parameters in treated animals compared to controls.

All animal findings come from non-human studies. They do not provide evidence for Cartalax effects in humans. This compound is not approved for any human clinical use. The findings are part of preclinical lab research only.

According to a review in Biogerontology (2010), Khavinson lab rodent studies showed changes in tissue-linked gene output markers after short bioregulator peptide treatment. Research focused on organ-specific cell biology in aging animal models. All work was conducted in non-human subjects.

Bioregulator	Tissue Source	Amino Acids	Research Focus
Cartalax	Cartilage	4	Cartilage cell gene output
Cardiogen	Cardiac	4	Cardiac cell gene output
Cortagen	Nerve	4	Cortical tissue gene models
Crystagen	Eye	3	Retinal cell culture studies
Epithalon	Pineal	4	Pineal gland aging models

How Does Cartalax Fit into Bioregulator Research?

Cartalax belongs to the bioregulator peptide class first described by Dr. Vladimir Khavinson. Bioregulators are short tissue-derived peptides studied for their effects on gene output in cell models. Each bioregulator is linked to a specific tissue of origin.

Cartalax is the cartilage-origin bioregulator in this class. Cardiogen is the cardiac-origin compound. Cortagen is the nerve-origin compound. All are sold as separate lyophilized research vials at Next Level Pharm. Each comes with its own COA showing HPLC purity and mass spec data.

How Is Research-Grade Cartalax Purity Confirmed?

Research-grade Cartalax is verified by HPLC and mass spec before shipping. HPLC confirms the compound is ≥99% pure in the production batch. Mass spec confirms the molecular weight matches the expected mass for the four-amino acid Cartalax sequence.

Short peptides have low molecular weights that mass spec identifies with high resolution. A mismatch would signal a truncated peptide or a wrong sequence. Shop research peptides at Next Level Pharm to view COA data. Every Cartalax batch is rejected if purity falls below ≥99%.

Frequently Asked Questions

What Is Cartalax?

Cartalax is a synthetic short peptide bioregulator derived from cartilage tissue fractions in Khavinson lab research. It is a chain of four amino acids with a low molecular weight. Lab studies have studied its effects on gene output in cartilage-type cell models. It is not FDA-approved and is sold for lab research use only, with a COA showing HPLC and mass spec verification on every batch.

What Is the Tissue Origin of Cartalax?

Cartalax was derived from cartilage tissue fractions by acid extraction and column sorting in Khavinson lab work. This cartilage origin shapes the focus of lab studies. Studies use cartilage-type cell lines and gene output markers linked to cartilage cell biology. Tissue origin is a key design feature of this research. It does not confirm selective activity in human cartilage tissue.

What Happened in Cartalax Cell Culture Studies?

Cell culture studies used cartilage-type cell lines treated with Cartalax. Researchers measured gene output changes in treated cells vs controls. These included mRNA levels for cartilage-linked genes. The proposed mechanism involves the short peptide entering the cell nucleus and binding chromatin near promoter regions. All findings come from in vitro models only.

What Happened in Cartalax Animal Model Studies?

Rodent model studies studied tissue-linked markers after Cartalax treatment. Changes in cartilage-related parameters were found in treated animals compared to controls in these studies. All findings come from non-human animal models. They do not provide human clinical evidence. Research-grade Cartalax is not approved for any human clinical application.

What Is a Bioregulator Peptide?

A bioregulator peptide is a short amino acid chain, typically 2-4 amino acids, derived from a specific tissue type. Khavinson lab research described this class of compounds in the 1980s onward. Each bioregulator is linked to one tissue of origin. Lab studies use cell lines from that same tissue. Synthetic bioregulators are made by SPPS and verified to ≥99% purity by HPLC and mass spec.

What Is the Molecular Weight of Cartalax?

Cartalax is a short peptide with a low molecular weight, consistent with a four-amino acid chain. Short peptides in the 2-4 amino acid range have molecular weights below 500 Da. Mass spec identifies these low masses with high detail. A correct mass spec result confirms the full four-amino acid sequence is present. Any mismatch signals a truncated or modified form.

How Does Cartalax Compare to Other Bioregulators?

Cartalax is the cartilage-origin bioregulator in the Khavinson class. Cardiogen is the cardiac-origin compound, and Cortagen is the nerve-origin compound. All are short peptides of four amino acids. Each is verified to ≥99% purity by HPLC and mass spec before shipping. Researchers should source each compound separately and verify its individual COA before any lab study.

How Is Research-Grade Cartalax Purity Confirmed?

HPLC confirms ≥99% purity for the Cartalax compound in each production batch. Mass spec confirms the molecular weight matches the expected mass for the four-amino acid sequence. A COA with both test results is needed for every batch shipped. Batches that fail either test are rejected before shipping to researchers.

Is Cartalax Available for Lab Research?

Yes, research-grade Cartalax is available as a lyophilized vial for lab use. Each vial is verified to ≥99% purity by HPLC and mass spec. It ships with a COA showing both results for that batch. Cartalax is not FDA-approved and is not for human use. Researchers should confirm the HPLC purity and mass spec data on the COA before any lab study begins.

Summary

Cartalax is a synthetic short peptide bioregulator derived from cartilage tissue fractions. Khavinson lab research described this four-amino acid compound and its tissue-linked effects on gene output in cell and animal models.

Cell culture studies showed changes in mRNA levels for cartilage-linked genes in treated cell lines. Animal studies showed changes in tissue markers in rodent models. None of these findings apply to human clinical use.

Research-grade Cartalax needs ≥99% purity by HPLC and mass spec on every batch.

What Should You Do Next?

Researchers sourcing Cartalax should verify three items on every COA. First, confirm HPLC purity is ≥99%. Second, confirm mass spec shows the correct molecular weight for the four-amino acid sequence. Third, record the lot number for tracking and records.

Shop research peptides. Every Cartalax batch ships with HPLC and mass spec data and a traceable lot number.

People Also Read

• Epithalon Research Explained: What Current Studies Show
• What Are Longevity Peptides? A Complete Research Review

About the Author

Next Level Pharm Research Team

Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to ≥99% purity via HPLC and mass spectrometry on every batch.

Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm products are intended for laboratory research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.